PDF
ePub
Citation
Print
Abstract
Background
This study compared the bronchodilator efficacy and safety of tiotropium inhalation capsules (18µg once daily) with a ipratropium metered dose inhaler (2 puffs of 20µg q.i.d.) in patients with chronic obstructive pulmonary disease (COPD).
Method
After the initial screening assessment and a two-week run-in period, patients received either tiotropium 18µg once daily or ipratropium 40µg four times daily over a period of 4 weeks in a double blind, double dummy, parallel group study. The outcome measures were the lung function, the daily records of the peak expiratory flow rate (PEFR), the patients' questionnaire, and the use of concomitant salbutamol. The forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC) were measured 5 minutes before inhalation, and 0.5, 1, 2 and 3 hours after inhaling the study drug on days 0, 14 and 28.
Result
In 16 centers, 134 patients with a mean (SD) age of 66 (7) years and a predicted FEV1 of 42 (12)% were analyzed. The trough FEV1 response was significantly higher in the tiotropium group than in the ipratropium group after a four-week treatment period. The weekly mean morning PEFR of the tiotropium group was consistently higher than that of the ipratropium group during the 4-week treatment period with differences ranging from 12.52 to 13.88 l/min, which were statistically significant. Tiotropium was well tolerated by the COPD patients during the 4-week treatment period and had a similar safety profile to ipratropium.
XML Download